Analyst Research
| Report Title | Price |
|---|---|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Edison Investment Research
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
NeuroSearch A/S Completes Sale of Laboratory Equipment and Office Furniture; Company Confirms FY 2013 Earnings Guidance
NeuroSearch A/S announced that it has completed a sale of the Company's laboratory equipment and office furniture amounting to a total of approximately DKK 10 million. The sale was conducted in collaboration with Troostwijk Auctions. The sale does not influence the expectations to the 2013 operation loss as the sales revenue will be recognized under discontinued operations. For the fiscal year 2013, NeuroSearch still expects an operating loss of approximately DKK 15 million on the assumption of release of the escrow amount of DKK 28.7 million by Teva upon satisfactory transfer of the Huntexil project. The saving relating to dismissals will be realized after 2013. The above expectations do not take into account any loss or profit arising out of a potential sale of the remaining NeuroSearch assets.
Latest Developments for Neurosearch A/S
- NeuroSearch A/S Sells Land and Building; Company Maintains FY 2013 Earnings Guidance
- NeuroSearch A/S Confirms FY 2013 Earnings Guidance
- NeuroSearch A/S Ends Transfer of Huntexil to Teva and Confirms FY 2013 Earnings Guidance
- NeuroSearch A/S to Initiate Negotiations about Layoffs and Prepares to Wind Up Current Activities, Company Confirms FY 2013 Guidance
Latest Key Developments in Biotechnology
- Share this
- Link this
- Digg this


Follow Reuters